Panasonic Museum Opens with Ceremony
Panasonic Corporation celebrated the opening of the Panasonic Museum in Kadoma City, Osaka, on March 7 - on the same day in 1918 the company was founded as Matsushita Electric Housewares Manufacturing Works by legendary business leader Konosuke Matsushita. An opening ceremony was held in the Konosuke Matsushita Museum on the premises, with 40 people in attendance including such dignitaries as the mayors of Kadoma and neighboring Moriguchi City, as well as company associates and executives.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180308005500/en/
The appearance of the Konosuke Matsushita Museum (Photo: Business Wire)
The Panasonic Museum consists of the Konosuke Matsushita Museum, the Hall of Manufacturing Ingenuity and the Sakura Hiroba, a garden with rows of sakura, or cherry trees, that was opened in April 2006. Adjacent to the Sakura Hiroba lies the former home of Mr. Matsushita, which the company plans to open to the public on a limited basis in the future.
The Konosuke Matsushita Museum, which was newly constructed, is a faithful reproduction of the company's third head office building completed in 1933, with the same appearance and at exactly the same location as the old building. Here visitors will be guided through a path of exhibits that introduce them to the 94 years of the founder's life, his thoughts on business and management philosophy.
The former Konosuke Matsushita Museum was renamed the Hall of Manufacturing Ingenuity after renovation. The building now houses around 150 home appliances, organized by category, that were carefully selected from among the Panasonic products offered in the past 100 years. Visitors can also trace the history of advertising by the company. Furthermore, a treasure house containing about 400 products that marked the company's history will also be open for viewing.
Additionally, three modern works of art have been placed on the premises as monuments to commemorate the 100th anniversary, as well as symbolizing the future development of the company as it is stepping into the next 100 years.
The Panasonic Museum will be open to the public on March 9. Going forward, Panasonic will enhance the permanent exhibits, while hosting field trip programs for children, who will lead the next generation, and workshops for the general public.
Address: 1006 Kadoma, Kadoma City, Osaka
Land Area: 25,329.7 m² (Sakura Hiroba: 16,198 m²)
- Konosuke Matsushita Museum - 1,906.19 m²;
- Hall of Manufacturing Ingenuity - 1,418.58 m²
Design & Construction: Takenaka Corporation
100th Anniversary Monuments:
Time Waterfall - Panel #2 by Tatsuo Miyajima
(Erected in the courtyard of the Hall of Manufacturing Ingenuity)
Floating form - vertical 2018 by Keiji Uematsu
(In front of the Hall of Manufacturing Ingenuity entrance)
Harmony with the breeze 2018 by Kozo Nishino (In the Sakura Hiroba)
Panasonic 100th Anniversary Portal
Global Communications Department
Global PR Office
Click here to go to Media Contact form
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28 | Pressemelding
Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (http://www.elektroniknet.de), a leading German electronics publication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005646/en/ Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05 | Pressemelding
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52 | Pressemelding
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50 | Pressemelding
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00 | Pressemelding
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on